DIMA Ploidy, Gleason Score,
Pathological Stage and Serum PSA
Levels as Predictors of Disease-Free
Survival in C-D(1) Prostatic Cancer
Patients Submitted to Radical
Retropubic Prostatectomy

Silverio, F. Di; D'Eramo, G; Buscarini, Maurizio; Sciarra, Alessandro; Casale, Paolo; Nicola, S. Di; Loreto, Andrea; Seccareccia, Fulvia; Vita, R. De

doi:10.1159/000474189

Cited by 19 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased overall surgical experience has certainly favoured the decreased operative morbidity rate from radical prostatectomy for clinical T3 cancer patients [129]. Reports on treatment outcomes in patients with clinical T3 cancer are currently available [129][130][131][132][133][134][135][136]. A recently published ECOG study in 98 node positive patients randomized to early versus deferred hormonetherapy reported an increased 5-year overall survival.…”

Section: Surgery Plus Hormone-therapymentioning

confidence: 99%

Cancer of the prostate

Bracarda

Cobelli

Greco

et al. 2005

Critical Reviews in Oncology/Hematology

102

View full text Add to dashboard Cite

Section: Surgery Plus Hormone-therapymentioning

confidence: 99%

Cancer of the prostate

Bracarda

Cobelli

Greco

et al. 2005

Critical Reviews in Oncology/Hematology

102

View full text Add to dashboard Cite

“…Studies evaluating DNA ploidy in prostate cancer have come to varying conclusions. Some studies on 45-850 (mean 139) cancers have suggested a relevant prognostic impact of ploidy (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20), while other studies on 33-447 (mean 122) cancers have failed to find significant associations (7,(20)(21)(22)(23)(24). Deletions affecting various chromosomal loci are a hallmark of prostate cancer.…”

Section: Introductionmentioning

confidence: 99%

The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer

Lennartz

Minner

Brasch

et al. 2016

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…6 studies provided a significant correlation of DNA-ploidy with overall survival after hormonal therapy in a multivariate design [169,[208][209][210][211]213]. 6 level 3b-studies [85], 7 of them multivariate, showed the same [110,169,[214][215][216][217]. 2 level 3b studies dealt with overall survival after AS [43,64] and report a significant correlation in a multivariate analysis.…”

Section: Methodologically Sufficient Papersmentioning

confidence: 99%

DNA-cytometric grading of prostate cancer Systematic review with descriptive data analysis

Böcking¹,

Tils²,

Schramm³

et al. 2014

Pathol Discov

View full text Add to dashboard Cite

Gleason-score <=6, assessed on core needle biopsies, is an essential prognostic parameter to offer the strategy of Active Surveillance (AS) to patients with locally confined cancers of the prostate. Yet, its interobserver reproducibility is low (48-70%) and its prognostic validity unsatisfactory. An option to complementary assess the malignant potential of these cancers are objective DNA-ploidy-measurements on existing biopsies. For that purpose chromosomal heterogeneity is indirectly quantified by DNA-cytometry resulting in DNA-grades of malignancy 1-4. This review systematically trawls and evaluates all scientific publications on the potential diagnostic and prognostic validity and the heterogeneity of DNA-ploidy measurements in cancers of the prostate between 1966 and 2013. Publications have been classified into Oxford levels of evidence and levels of significance were given for the correlation of DNA-ploidy with different clinical outcomes. 114 scientific articles had to be excluded because of different methodological reasons. All but one of the 67 methodologically acceptable articles report on a significant diagnostic resp. prognostic significance of DNA ploidy measurements in cancers of the prostate. 8 level 1b studies report that DNA-ploidy, assessed on punch biopsies independently predicts organ confinement as assessed after radical prostatectomy. 18 level 2b studies prove that DNA-ploidy measurements add statistically significant information to the Gleason-score. 16 level 2b investigations report a significant correlation of DNA-ploidy with recurrence-free survival. 15 level 2b studies document a significant correlation with overall survival after different types of therapy. 5 level 2b investigations prove a significant correlation with local recurrence or progress after radical prostatectomy. 3 level 2b publications show a significant correlation of DNAploidy with the occurrence of lymph node-or bone metastases after radical prostatectomy. 1 level 2b study documents the additional prognostic value of DNA-ploidy measurements over conventional subjective grading in prostate cancer patients under AS. All existing 15 narrative reviews on selected articles dealing with prognostic DNA-cytometry in cancers of the prostate are in favor of this method. Prospective level 1b studies, especially those proving the validity of DNA ploidy measurements to predict non-progression in patients with clinically insignificant low-grade low stage cancers of the prostate eligible for Active Surveillance additionally to the Gleason-score are still missing.

show abstract

DIMA Ploidy, Gleason Score, Pathological Stage and Serum PSA Levels as Predictors of Disease-Free Survival in C-D(1) Prostatic Cancer Patients Submitted to Radical Retropubic Prostatectomy

Cited by 19 publications

References 15 publications

Cancer of the prostate

Cancer of the prostate

The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer

DNA-cytometric grading of prostate cancer Systematic review with descriptive data analysis

Contact Info

Product

Resources

About